#### Summary of Syncope Reports to Vaccine Adverse Event Reporting System (VAERS) January 1, 2005 – July 31, 2007

# Advisory Committee on Immunization Practices Atlanta, GA October 25, 2007

Barbara Slade, MD
Wan-Ting Huang, MD
Immunization Safety Office
Office of the Chief Science Officer
Centers for Disease Control and Prevention



### Vasovagal Syncope

- Transient loss of postural tone and consciousness with spontaneous recovery
  - Bradycardia, vasodilatation or hypotension resulting in decreased brain perfusion
  - Due to abnormal sympathetic reflex
- Elicited by a variety of stimuli in settings of fear or emotional distress
- Occurs after medical procedures, including vaccinations



### General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)<sup>1</sup>

"..., although syncopal episodes are uncommon ... vaccine providers should strongly consider observing patients for 15 minutes after they are vaccinated. If syncope develops, patients should be observed until symptoms resolve."

<sup>1</sup>MMWR 2006; 55 (No. RR-15)

# Vaccine Adverse Event Reporting System (VAERS)

- National passive surveillance system
- Jointly operated by CDC and FDA since November 1990
- Covering all U.S. licensed vaccines
- Receives >15,000 reports per year
- Subject to well-described limitations including underreporting and reporting bias



### Objectives

- Describe trends in syncope events reported to VAERS
- Characterize post-immunization syncope
- Identify potential areas for further research



### Published VAERS Data on Syncope

- Serious injuries with at least one fatality have occurred<sup>1</sup>
- 89% occurred within 15 minutes<sup>2</sup>
- VAERS data, 1990-2004<sup>3</sup>
  - Total number of reports: 3,168
  - 35% were among persons aged 10-18 years
  - 14% resulted in hospitalization for injury or medical evaluation

```
<sup>1</sup>Woo EJ et al. Arch Pediatr Adolesc Med 2005; 159: 1083

<sup>2</sup>Braun MM et al. Arch Pediatr Adolesc Med 1997; 151: 255-9

<sup>3</sup>MMWR 2006; 55 (No. RR-15)
```



#### Methods

- Population:
  - VAERS reports received Jan 1, 2005 Jul 31, 2007
- Case definition:
  - MedDRA® coding terms¹ "syncope" or "syncope, vasovagal"
  - Case-patients aged ≥ 5 years
  - Syncope onset < 1 day after immunization</li>
  - Vaccines involved in syncope reports
- Available records reviewed for selected reports

### Adverse Events\* Reported to VAERS, 2002 – 2007

Year	2002 – 2004		2005 – 2007	
	N = 23,934		N = 25,861	
Adverse events	No.	(%)	No.	(%)
Syncope	203	(1)	463	(2)**
Serious+ syncope	20	(10) <sup>¶</sup>	33	(7)¶

<sup>\*</sup>Case-patients aged ≥ 5 years


¶Proportion of serious reports among all syncope reports, p=0.2758 8



<sup>\*\*</sup> Significant increase in syncope reports in 2005—2007, p=0.0001

<sup>\*</sup>Defined by FDA as resulting in death, life-threatening illness, hospitalization, or disability; according to information provided by the reporter of the adverse event

### Syncope\* reported to VAERS, January 1, 2004 - July 31, 2007



\*Case-patients aged ≥5 years Date of report received (month)


\*MCV4: meningococcal conjugate vaccine; Tdap: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine; HPV: quadrivalent human papillomavirus vaccine

\*\*Date of ACIP Vaccines For Children (VFC) Program vote

### Syncope reported to VAERS, by age and sex, January 1, 2005 - July 31, 2007

(N = 463)

Syncope reported to VAERS, 2002-2004







### Vaccines Associated with Syncope Reports in VAERS, 2005 - 2007

	One vaccine given N = 302		Multiple vaccines given concurrently N = 161	
	No.	(%)	No.	(%)
HPV	156	(52)	63	(39)*
MCV4	15	(5)	75	(47)*
Tdap	11	(4)	53	(33)*
HPV, MCV4 and/or Tdap	182	(60)	109	(68)
Other vaccine(s)	120	(40)	52	(32)

<sup>\*</sup>Not mutually exclusive categories



## Syncope Associated with Injuries in VAERS Reports, 2005 – 2007 (N = 41\*)

- Adolescent (11-18 years), N = 31
  - Females, N = 22 (71%)
  - Males, N = 9 (29%)
- Syncope onset after immunization:
  - 20 (49%) within 5 minutes
  - 33 (80%) within 15 minutes
- Serious+ cases, N = 10 (24%)

\*Excludes 14 cases with unknown onset intervals

+Defined by FDA as resulting in death, life-threatening illness, hospitalization, or disability; according to information provided by the reporter of the adverse event



# Example of injury related to post-vaccination syncope

A 13-year-old girl fainted within 10 minutes of receiving HPV and MCV. She fell backward, hit her head on carpeted floor of the clinic and was admitted to the pediatric intensive care unit because of skull fractures and subarachnoid hemorrhage.



### Cases Aged ≥50 Years with Syncope Onset ≤12 Hours after Immunization, 2005 - 2007

	Ages ≥50 years, n=20		
	No.	(%)	
Gender*			
Females	16	(80)	
Males	3	(15)	
Pre-existing medical conditions	14	(70)	
Onset time			
≤ 5 MIN	5	(25)	
≤15 MIN	6	(30)	
Serious** cases (2 deaths)	8	(40)	
Associated with influenza vaccines	12	(60)	

<sup>\*</sup>One report with missing information was not included

<sup>\*\*</sup> Defined by FDA as resulting in death, life-threatening illness, hospitalization, or disability; according to information provided by the reporter of the adverse event



#### Limitations

- Cannot calculate syncope incidence rate based on VAERS data
  - Underreporting of adverse events
  - Lack of data on vaccine doses administered
- VAERS MedDRA® coding terms may not reflect diagnosis accurately
- Most non-serious reports were not reviewed
- Cannot determine if syncope related to vaccine (e.g., HPV), targeted age group or both



#### Conclusions

- Since 2005, increase seen in number of VAERS syncope reports among:
  - Females aged 11-18 years
  - Non-serious reports
  - Reports associated with vaccines recommended for adolescents
- Syncope-related injury rarely occurred, can be serious, and may be preventable



#### Areas for Research

- Address age-specific incidence of syncope associated with immunization
- Evaluate adherence to waiting period
- Evaluate effectiveness of waiting period and other measures to prevent secondary injury
- Provide evidence-based interventions for use by clinicians to predict/prevent syncope after immunization



### Remind Vaccine Providers of Current Recommendations

Advisory Committee on Immunization Practices, 2006<sup>1</sup>

"..., vaccine providers should strongly consider observing patients for 15 minutes after they are vaccinated."

American Academy of Pediatrics, 2006<sup>2</sup>

"Personnel should be aware of presyncopal manifestations and take appropriate measures to prevent injuries..."

"... having vaccine recipients sit or lie down for 15 minutes after immunization could avert many syncope episodes and secondary injuries."

<sup>1</sup>MMWR 2006; 55 (No. RR-15) <sup>2</sup>American Academy of Pediatrics. 2006 Red Book: Report of the Committee on Infectious Diseases, 27<sup>th</sup> ed.



### Acknowledgements

- CDC ISO
  - Karen Broder
  - Julianne Gee
  - John Iskander
  - Tanya Johnson
  - Elaine R. Miller
  - Laura Leidel
- CDC NCHHSTP
  - Lauri Markowitz

- CDC NCIRD
  - Andrew Kroger
- FDA CBER
  - Robert Ball
  - M. Miles Braun
  - Hector Izurietta
  - Andrea Sutherland
  - Emily J. Woo

